🔴 Telix Pharmaceuticals is trading 6.7% down in pre-market with no clear company-specific catalyst

Telix Pharmaceuticals is trading 6.7% down at $11.03, with no clear company-specific announcement explaining the pre-market decline.

• Shares fell from the August 14 close of $11.82.
• Investors may be positioning cautiously ahead of the scheduled half-year results release on August 20, 2026; the event was previously announced and is not a fresh catalyst.
• The broader pre-market market is modestly mixed, providing no clear explanation.